Pfizer's COVID-19 vaccine trial shows long-term efficacy in adolescents


FE Team | Published: November 22, 2021 19:01:56 | Updated: November 23, 2021 09:15:41


Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS

Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100 per cent effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide, reports Reuters.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorised for emergency use in people aged 12-15 years by the US Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.

Share if you like